Cyclosporine Eyedrops Under Review for Vernal Keratoconjunctivitis
Vernal keratoconjunctivitis is a rare allergic eye disease that affects the pediatric population and results in severe inflammation of the surface of the eye.
Ocular Allergy/Inflammation
Preservative-Free Alaway Gets FDA Approval for OTC Use
The new formulation does not contain benzalkonium chloride.
New Drug Product: Durysta
This slideshow shows drug information for Durysta. Click here for the complete Durysta monograph.
Olopatadine 0.7% Eye Drops Approved for Sale Over-the-Counter
The FDA has approved Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride 0.7%; Alcon) ophthalmic solution, formerly prescribed as Pazeo®, for sale over-the-counter.
Eysuvis Under Review for Dry Eye Disease
The FDA has accepted for review the New Drug Application for Eysuvis™ (loteprednol etabonate ophthalmic suspension; Kala Pharmaceuticals) 0.25% for the treatment of dry eye disease.
Zerviate Ophthalmic Solution Now Available for Allergic Conjunctivitis
Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.
Tobradex ST Now Available for Inflammatory Eye Conditions With Bacterial Infection
Tobradex ST contains tobramycin, an antibacterial drug, and dexamethasone, a potent corticosteroid.
Thyroid Eye Disease Treatment Gets FDA’s Priority Review
The FDA has accepted for priority review the Biologics License Application (BLA) for teprotumumab (Horizon Therapeutics) for the treatment of active thyroid eye disease.
Inveltys Now Available for Post-Op Ocular Pain, Inflammation
Data from two Phase 3 studies showed a greater proportion of patients treated with Inveltys having complete resolution of ocular inflammation and pain compared with placebo.
Dextenza Approved for Ocular Pain Following Ophthalmic Surgery
The approval was based on data from 2 vehicle-controlled Phase 3 trials.
